<DOC>
	<DOC>NCT01408615</DOC>
	<brief_summary>This observational study will examine the safety and efficacy profile of Elonva (corifollitropin alfa) when administered in Korean women undergoing controlled ovarian stimulation (COS) in combination with a gonadotropin-releasing hormone (GnRH) antagonist for the development of multiple follicles in an assisted reproductive technology (ART) program.</brief_summary>
	<brief_title>A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Infertility, Female</mesh_term>
	<criteria>Women with an indication for COS prior to in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) who meet the criteria as mentioned in the current Korean ELONVA local label Hypersensitivity to the active substance or to any of the excipients Tumors of the ovary, breast, uterus, pituitary or hypothalamus Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause. Primary ovarian failure Ovarian cysts or enlarged ovaries A history of OHSS A previous COS cycle that resulted in more than 30 follicles â‰¥ 11 mm measured by ultrasound examination Basal antral follicle count &gt; 20 Fibroid tumors of the uterus incompatible with pregnancy Malformations of the reproductive organs incompatible with pregnancy Pregnancy Polycystic ovarian syndrome</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>